Quality Guarantee



Our commitment is to provide every client with a viable source of stem cells that will result in the best treatment outcomes should they ever be needed. We stand behind our products 100% and back our commitment with the highest Quality Guarantee in the Cord Blood Banking industry.

Quality Guarantee

Our guarantee states that if your child’s cord blood stem cells fail to engraft during a transplant due to a product defect, we will replace them with a suitable match from our public banking inventory. Should a suitable match not be available, we will pay up to $100,000 to defray the cost of procuring an alternative stem cell source as determined by your doctor.

Terms & Conditions

This Quality Guarantee is not intended to guarantee the result of a medical procedure. It is intended to apply only in the event that cord blood stem cells are required for hematopoietic transplant subject to the exclusions that are noted below.

In addition, the Quality Guarantee will not be extended to the Parent(s) unless the Parent(s) has completed and returned to Cord for Life® both Client Contract and the Health History Questionnaire.

Subject to the requirements set forth below, if a Client’s cord blood is processed and stored by Cord for Life® and is used for hematopoietic stem cell transplantation using recognized medical practices and fails to engraft, Cord for Life® will pay the Parent(s) $100,000. This payment to the Parent(s) is intended to partially defray the costs to procure alternative stem cells from a public cord blood bank, in the event of product failure.

Definition of Engraftment:

Engraftment is defined as three consecutive measurements in which the transplant recipient’s peripheral blood absolute neutrophil count (ANC) is equal to or greater than 500/microliter with the first measurement occurring within 100 days of transplantation. The engrafted cells must be of donor origin.

Requirements

In order to qualify, Client must complete and return the required Enrollment Packet, including the Enrollment Agreement, the Informed Consent, the Payment Plan Form and Credit Card Authorization, and the Health Questionnaire in entirety.

Required documentation of failure to engraft includes:

  1. Signed statement from the treating physician attesting that the transplanted donor product did not engraft.
  2. Laboratory records documenting proof of non-engraftment.
  3. Written documentation that all third party payers involved in paying for collection, storage or transplant have been notified and declined coverage.
  4. Or, Cord for Life®’s written notice of its inability to produce the cord blood unit for hematopoietic transplant.

HLA tissue typing: donor cells must be at least a 4 out of 6 match to the recipient.

The cord blood thawing procedure must be a validated procedure used by the transplant facility and the cord blood must be administered immediately (within 1 hr) upon thawing.

The cryopreserved cord blood must be used in an autologous stem cell transplant for homologous use (hematopoietic reconstitution) by the donor or by a first-degree or second-degree blood relative (the “Immediate Family”). The cryopreserved cord blood must be administered under the direction of a transplant physician in a FACT accredited medical facility qualified by an Institutional Review Board (IRB) for stem cell transplantation. 


Exclusions:

The Quality Guarantee does not include:

  1. Cord blood units that are collected by any method outside of Cord for Life®’s standard operating procedure, even if such cord blood units have been stored by Cord for Life® with Parent(s)’approval. 

  2. Transplantation of umbilical cord blood with less than 2 x 107 total nucleated cells per kilogram of recipient’s weight, even if such cord blood units have been stored by Cord for Life® with Parent(s)’ approval. 

  3. Transplantation of umbilical cord blood with less than 1 x 105 CD34+ cells per kilogram of recipient’s weight, even if such cord blood units have been stored by Cord for Life® with Parent(s)’ approval. 

  4. Co-transplant with supplemental stem cell sources (e.g., additional cord blood, peripheral blood or bone marrow). 

  5. Transplantation other than to biological family members. Biological family members are defined as the Child (i.e., the cord blood donor) and his/her biological Parents and biological siblings. 

  6. Experimental transplantation protocols, defined below as any of the following: 

    • Mini –transplants
    • Transplantations using stem cells that, prior to administration to the patient, have been subject to more than minimal manipulation including, but not limited to, the following:
    • Stem cell expansion
    • Extensive laboratory culture or positive or negative cell selection 

    • Gene therapy 

    • Transplantation using stem cells that are subject to a US Food and Drug Administration investigational new drug application or foreign equivalent.
    • Use of an investigational drug by the transplant recipient within 100 days of transplantation.
    • Cells transplanted for non-homologous use.

The Quality Guarantee is not available to:

  • The Quality Guarantee is not meant to cover any costs that are reimbursed by Third Party Payors, including, but not limited to the following:
  • Individuals whose cord blood stem cell collection, storage, or transplant fees are paid in full or part by Medicare, Medicaid, Blue Cross/Blue Shield or other commercial insurance company the is the payor for coverage provided by a health plan.
  • Individuals whose cord blood stem cell collection, storage, or transplant fees are paid in full or part by third-party payors in Massachusetts and Michigan.

Notification of Insurance:

By accepting payment via the Cord for Life® Quality Guarantee, the recipient agrees to notify any third-party payor who paid in part or wholly for the collection, storage, or transplant, of the existence of this Quality Guarantee, the amount paid and all other terms and conditions. Prior to payment of the Quality Guarantee, Cord for Life® must have proof, in writing, that all third-party payers involved in paying for collection, storage or transplant have been notified.

Additional Information:

This $100,000 ® Quality Guarantee is valid for Clients who have signed Cord for Life®’s standard contract and Agreement covering cord blood services and whose payments to Cord for Life® for services are current.

Any and all payments made by Cord for Life® under the Quality Guarantee are made at the sole discretion of Cord for Life®.

The guarantee only covers the cost of procuring replacement stem cells and does not cover the cost of medical procedures or other related fees.

Any applicable federal, state or local taxes associated with the payments defined herein are the sole responsibility of the Client. 

Client should note that banking a newborn’s cord blood does not guarantee that the umbilical cord blood will be a match for a family member, that a cord blood stem cell transplant would be the first or best course of treatment for any particular disease or that a child’s own cord blood is useful for every disease treatable by stem cell transplantation. A medical care provider ultimately decides whether the use of your Child’s cord blood sample is indicated, based on the nature and progression of the disease and the HLA matching for donor and recipient. This offer is independent from and in no way diminishes the effect of Cord for Life®’s limitation of liability set forth in its Agreement with client. 


This $100,000 Cord for Life® Quality Guarantee is available only to Clients enrolling under the new service Agreement and associated fee structure beginning on or about May 1, 2018. The Cord for Life® Quality Guarantee is not retroactive to enrollments occurring before May 1, 2018. 



LATEST ARTICLES


October 4, 2018

Located in Altamonte Springs, Cord For Life® Inc. is a local umbilical cord blood bank that specializes in public and private stem cell processing and cryopreservation. Cord For Life® has operated in the Central Florida area since 1993, and to date has processed over 15,000 cord blood units from across the United States. In addition […]

June 7, 2018

So much research is going on with stem cells from cord blood as scientists work to unlock the secrets of stem cells.  Much of the research centers on the anti-inflammatory properties of stem cells from umbilical cord blood. Medical research into stem cells is ongoing, offering the potential to treat diseases or injuries that have […]

June 7, 2018

Stem cells perform three important functions:  1.  They renew themselves; 2. Differentiate into other cells; and 3. Renew other cells. Hematopoietic stem cells (HSCs) can restore the immune system following  chemotherapy or radiation for leukemia, lymphoma, and other life-threatening diseases. Historically, HSCs have only been available from bone marrow and peripheral blood transplants.  As cord […]

Aspect image
Aspect image
Aspect image
Aspect image
Aspect image

Ready to sign-up for cord blood banking?

Reserve your Cord Blood Collection Kit in time to bring it with you when you go into labor.  Give your newborn every advantage with cord blood banking!


Enroll Today


Donate Cord Blood

By donating your newborn’s cord blood, you are joining a nationwide effort to create a genetically diverse inventory of stem cells for transplant to a child.


Donate Today

logo-cord

Our purpose is to provide the expectant mothers with information necessary to discover the lifesaving potential of umbilical cord blood.

Copyright Cord for Life 2019. All rights reserved.

ATILLA KONDOROSI

Mr. Kondorosi has been involved with the hospitality and hotel industry for most of his life.  From 1969 through 1985, he held various positions at the international InterContinental Hotels chain, including various senior management roles.  After his transitioning to the USA, he moved into the real estate business and held a variety of positions.  Recently he has held te position of Director of Sales for Prestige Homes, Inc. part of Goldrich and Kest Industries headquartered in California since 1957.  Mr. Kondorosi represented the successful sale of 386 homes in the Bel Air Crest Development, including re-sales over the past several years, various high end listings and sales in prominent locations such as Malibu, Pacific Palisades, Bel Air, Beverly Hills and other parts of the west-side Los Angeles area.

Mr. Kondorosi is also the founder and President of EDKO Trade, Inc., and international real estate and trading company involved in promoting and closing transactions between various companies and individuals located around the world.  Since 2000, he has also been involved in various international and foreign innovative startup companies in various capacities including CEO, board member or in a consulting role.  Mr. Kondorosi received a Juri Doctor degree from Janus Pannonius University in Hungary in international law.  He also was a professor at the Budapest Business School / Faculty of Commerce, Catering and Tourism in Hungary.

In addition, Mr Kondorosi has served on the Board for the Regency Club from 2008 through 2011, a private business organization started by David Murdock 30 years ago in Los Angeles.

Deborah A. Sardone

Ms. Sardone has over 30 years of clinical laboratory experience as a Clinical Laboratory Technologist, including over 25 years with Central Florida Regional Hospital (CFRH). She was Supervisor of Quality Assurance, Safety and Education at CFRH for 11 years, held the positions of Blood Bank Supervisor for 11 years, and Hematology Supervisor for 1 year. She has participated in both sides of the inspection process, serving on the College of American Pathologists Inspection team for CAP Hospital Accreditation in Florida, and assisting in receiving accreditation by The Joint Commission (TJC), American Association of Blood Banks (AABB), and Food and Drug Administration (FDA) through the inspections of the clinical laboratory.

Ms. Sardone is licensed by the State of Florida as a Clinical Laboratory Technologist in Immunohematology, Hematology, Serology and Clinical Chemistry. She is a certified Clinical Laboratory Technologist with the American Society of Clinical Pathologists (ASCP).

Ms. Sardone serves as Manager of Quality Assurance and Regulatory Affairs at Cord For Life®, Inc. overseeing all licensing and regulatory agencies to ensure that the highest quality in all aspects of cord blood collection, processing, and storage is maintained.

Ms. Sardone’s skills and knowledge in blood banking and quality assurance have enabled her to establish, implement and maintain a superior quality system that meets and exceeds all standards and regulatory requirements for Cord For Life®, Inc.

Personal Background:

  • Sardone is a graduate of The City University of New York in Medical Laboratory Technology.
  • Sardone is licensed in Florida as a Clinical Medical Technologist and she is nationally recognized as ASCP Certified.
  • Sardone enjoys photography and dancing.

Donald Hudspeth

Mr. Hudspeth has over 17 years of clinical laboratory experience as a certified Medical Technologist (ASCP), including ten years with the University of North Carolina Hospitals. Mr. Hudspeth is licensed by the State of Florida as a Clinical Laboratory Supervisor in Immunohematology, Hematology, Serology, Clinical Chemistry, Molecular Pathology and Microbiology as well as a Clinical Laboratory Scientist, is a registered Technologist with the American Society of Clinical Pathologists and a member of the American Society of Blood and Marrow Transplantation (ASBMT).

He has also enjoyed teaching Immunology to Clinical Laboratory Science and medical school students at UNC while working in the UNCH clinical labs. At Cord For Life®, Mr. Hudspeth serves as Chief Operating Officer, overseeing all operations and the daily laboratory operations to ensure that the highest quality in all aspects of donor selection and cord blood collection, processing, and storage is maintained. He also works with Quality Assurance to ensure full compliance by Cord For Life® to all applicable regulations. Mr. Hudspeth has sat on numerous cord blood focused committees and advisory groups.

Additionally, Mr. Hudspeth served as the Clinical Investigator for Cord For Life® as they evaluated and approved a new processing methodology to isolate stem cells from cord blood while depleting the unwanted red cells. Mr. Hudspeth works with groups, individuals, or government agencies to bring cord blood banking to countries around the world. He is responsible for training medical professionals worldwide in cord blood processing at our Florida location. In addition, he travels overseas to assist in the initial setup and implementation of the new facilities to ensure their compliance and quality. Mr. Hudspeth has assisted in opening new cord blood facilities in Europe and in SE Asia.

Personal Background:

  • Mr. Hudspeth received his Bachelor’s degree in Clinical Laboratory Sciences from the University of North Carolina at Chapel Hill.
  • “Eagle Scout with Five Palms”
  • Avid golfer with a 14 handicap.

Donald R. Drake III, Ph.D

Don joined Sanofi Pasteur VaxDesign in 2005 and has served as Director of Immunological Research since 2009. He has had a long-standing interest in the immune system, particularly the interaction between viruses and elements of the adaptive immune system, since initiating his graduate studies at Emory University in Atlanta, GA.

As a post-doctoral fellow at the University of Virginia, he was awarded funding from the Cancer Research Institute and received an Interdisciplinary Training Grant in Immunology from the National Institutes of Health to study CD8+ T cell immunity against influenza virus.

At VaxDesign, Don leads a team developing and optimizing the MIMIC® System to permit the evaluation of human adaptive immunity (cellular and humoral responses) against vaccine candidates, biologics, and other immunomodulators in a pre-clinical setting. He is an author on a variety of patents and peer-reviewed journal publications.

Kelli Cable

Mrs. Cable brings over 20 years of experience to Cord For Life® directing the Client Services, Account Management and Personnel departments. She began working in the cord blood industry in December of 2006. In addition, Ms. Cable is actively involved in marketing for the company.

Personal Background:

  • Mrs. Cable is married and has two boys.
  • In 1994, Ms. Cable moved to Orlando from Boulder, Colorado.
  • Has a passion for travel and enjoys watching NFL games, cheering on her favorite team, the Denver Broncos.

Richard R. Gammon, M.D.

Dr. Richard R. Gammon joined Florida’s Blood Centers (FBC) in 2005 and is responsible for ensuring that the organization’s medical practices, policies and testing remain at the forefront of the blood-banking industry. He received his undergraduate degree from Gannon University in Erie, Pennsylvania and medical degree from Hahnemann University in Philadelphia.

He completed his residency at The Ohio State University and his fellowship at the University of Virginia. He also serves as an assistant professor of pathology at the University of Central Florida College of Medicine. He has served as President and Technical Committee Chair of the Florida Association of Blood Banks. He currently serves as the Chair of the Scientific Medical and Technical Committee and Chair of the Journal Club for America’s Blood Centers.

He is an assessor and abstract reviewer for AABB and is a manuscript reviewer for the journal Transfusion. He is the co-recipient of a 2011 ABC Foundation Grant for the Get Healthy Wellness Program. Dr. Gammon’s research has been published in various peer-reviewed journals and he has been a featured speaker at numerous national and international conferences on blood banking and transfusion medicine.

Robert Parkhill, Ph.D

Dr. Parkhill directs operations at the Sanofi Pasteur VaxDesign Campus, which designs, develops, and manufactures in vitro models of the human immune system. Their mission is to prevent infectious disease by forecasting vaccine responses before clinical trials, and create a competitive advantage by providing predictive in vitro immunological models and assays. Dr. Parkhill holds a PhD in Material Science and Inorganic Chemistry for Oklahoma State University.

Robert W. Pollack, M.D., R. PH.

Dr. Pollock was originally from Ohio where he majored in pharmacy at Ohio Northern University. After graduation he worked as a pharmacist and attended The Ohio State University where he majored in chemistry and graduated in biochemistry.

In 1992 he attended Wright State University School of Medicine in Dayton Ohio, after graduating from medical school he completed his residency at Orlando Regional Medical Center in anatomic and clinical pathology, then a two year fellowship in clinical molecular genetics at All Children’s Hospital in St Petersburg Florida. After completing his fellowship in genetics, he became Medical Director for Central Florida Blood Bank for 3 years where he took great interest in the stem cell donation program.

After leaving the blood bank, Dr Pollock became Assistant Director in Molecular Genetics for the Centers of Advanced Diagnostics which at the time was a division of Ameripath. After the restructuring of the Orlando operation, Dr Pollock found himself back in blood banking. He was medical director for BloodNetUSA in Lakeland, Florida prior to its merger with Florida Blood Services.

Sara Irrgang, M.D

During the last two years of Medical School, Dr. Irrgang was in the United States Navy 1915 Ensign Program and completed a clerkship at the Naval Hospital at Charleston, South Carolina as well as a research clerkship at the Naval Aerospace Institute at Pensacola, Florida.

Dr. Irrgang completed her four year Pathology residency at Baylor University Medical Center, and her internship at the University District Hospital, Rio Piedras in San Juan, Puerto Rico. Currently, Dr. Irrgang is Board Certified in Anatomic and Clinical Pathology and licensed in the states of South Carolina, Texas, New Jersey and Florida and she is an Associate Medical Examiner at the District Nine Medical Examiners Office.

Dr. Irrgang is a fellow at numerous organizations including; The College of American Pathologists, National Association of Medical Examiners, Florida Association of Medical Examiners, Seminole County Medical Society, and the Florida Medical Society.

Personal Background:

  • Dr. Irrgang received a Bachelor of Science degree in Pharmacy from the University of South Carolina.
  • Attended the Medical College of South Carolina at Charleston where she earned a Medical Doctorate Degree.
  • Dr. Irrgang has a passion for breeding show horses
  • Dr. Irrgang is a 4-H leader in Lake County, Florida

Tisha M. Foster, M.D

Dr. Tisha M. Foster joined Florida’s Blood Centers (FBC) in 2008 and is responsible for therapeutic apheresis, cellular therapies, and FBC’s participation in the National Marrow Donor Program. She received her undergraduate degree from the University of Central Oklahoma and her medical degree from the University of Oklahoma. She completed her residency at the University of Oklahoma Health Sciences Center and her fellowship at the Medical College of Wisconsin/Blood Center of Wisconsin. Prior to joining FBC, Dr. Foster served as medical director at BloodNetUSA in Lakeland (Fla.), where her responsibilities included supervision of the Transfusion Service Laboratory at Lakeland Regional Medical Center, donor eligibility, therapeutic apheresis, and ensuring regulatory compliance throughout the blood center.